ePrints

New prognostic biomarkers in metastatic castration-resistant prostate cancer

Lookup NU author(s): Dr Pasquale RescignoORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. Prostate cancer is one of the most frequent cancers in men and is a common cause of cancer-related death. Despite significant progress in the diagnosis and treatment of this tumor, patients who relapse after radical treatments inevitably develop metastatic disease. Patient stratification is therefore key in this type of cancer, and there is an urgent need for prognostic biomarkers that can define patients’ risk of cancer-related death. In the last 10 years, multiple prognostic factors have been identified and studied. Here, we review the literature available and discuss the most common aberrant genomic pathways in metastatic castration-resistant prostate cancer shown to have a prognostic relevance in this setting.

Publication metadata

Author(s): Conteduca V, Mosca A, Brighi N, de Giorgi U, Rescigno P

Publication type: Review

Publication status: Published

Journal: Cells

Year: 2021

Volume: 10

Issue: 1

Online publication date: 19/01/2021

Acceptance date: 13/01/2021

ISSN (electronic): 2073-4409

Publisher: MDPI

URL: https://doi.org/10.3390/cells10010193

DOI: 10.3390/cells10010193

PubMed id: 33478015

Share